NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

SMMT | NASDAQ

$17.13 -$0.46 | -2.62%

TREND SIGNAL: Signal available — unlock to view

|2026-10-07

Next Earnings: Oct 19, 2026

Add to favoritesFavorite

Company Overview:

Market Cap: $13.67B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $12.07 - $29.23

10 Year SMMT Performance Metrics:

Total Return (with DRIP): 63.6% (5.05% CAGR)

Total Return (no DRIP): 63.6% (5.05% CAGR)

Share Price: 63.6% (5.05% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $16,361

Total Return $ (with DRIP): $6,361

SMMT Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

SMMT Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

SMMT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

SMMT - Revenue

SMMT Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Earnings Per Share (EPS)

SMMT EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Net Income

🔓 See the full chart40% off right now · 7-day free trial

SMMT Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

SMMT EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

SMMT Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

SMMT Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

SMMT Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

SMMT Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

SMMT Shares Outstanding CAGR:1Y: 4.79%2Y: 4.85%5Y: 53.25%10Y: 28.90%

SMMT - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

SMMT Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

SMMT Stock-Based Comp CAGR:1Y: -80.44%2Y: 148.93%5Y: 79.65%10Y: 63.01%

SMMT - Expenses

🔓 See the full chart40% off right now · 7-day free trial

SMMT Expenses CAGR:1Y: 0.00%2Y: 292.53%5Y: 45.01%10Y: 43.16%

SMMT - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

SMMT - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

SMMT - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

SMMT - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

SMMT - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

SMMT - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

SMMT - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

SMMT Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

SMMT Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

SMMT - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SMMT Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SMMT Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SMMT Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

SMMT Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

SMMT - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

SMMT Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

SMMT Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

SMMT Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

SMMT Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

SMMT Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

SMMT - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

SMMT Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for SMMT

Based on past 10-year performance, here are SMMT growth metrics:

Share price CAGR of +5.05%
Dividend CAGR of +0%

Using SMMT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	SMMT (DRIP)	SMMT - No DRIP
Current Price	$17.13	$17.13
Start Shares	583.77	583.77
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	583.77	583.77
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$17.13	$17.13
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - SMMT

NOTE: Above numbers are our estimate based on SMMT's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

Company Info

Summit Therapeutics Inc. (SMMT) had its IPO on 2015-03-05, and is traded on NASDAQ stock exchange.

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

SMMT website: https://www.smmttx.com

Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

Combined 55% Lifetime Discount

DCF Model — SMMT

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $17.13

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →